Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 864.25k | -- | 1964 |
| Dr. Uday B. Kompella Ph.D. | Co-founder & Independent Director | 60k | -- | 1967 |
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 598.06k | -- | 1983 |
| Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A. | Principal Financial Officer & Principal Accounting Officer | -- | -- | -- |
| John Kouch J.D. | General Counsel | -- | -- | -- |
| Ms. Tiffany J. Hamilton M.B.A. | AVP & Head of Corporate Communications | -- | -- | -- |
| Ms. Kristen Craft | Head of People & Culture | -- | -- | -- |
| Mr. Michael Shine M.B.A. | Senior Vice President of Commercial | -- | -- | -- |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality | -- | -- | -- |
| Dr. Huma Qamar CMI, M.D., M.P.H. | Chief Medical Officer | -- | -- | 1984 |
Ocugen, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 95
Description
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Ocugen, Inc. Earnings Date
Recent Events
February 11, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission